“You get what you pay for” has a nice ring to it. But it does not accurately describe the situation of those buying prescription pharmaceuticals in the US. President Trump, who has vowed to lower drugs prices by as much as 80 per cent, may finally have found a useful target for his sledgehammer.
Drug prices have been a long-standing headache for successive US administrations. The complex system through which private insurers and state programmes buy pharmaceuticals means they pay a multiple of what comparable products cost in other countries.
您已閱讀19%（548字），剩余81%（2394字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。
成為高端會員，閱讀高端專享內容
如您已經是高端會員，請點擊這里登錄